Enlarged cavum septum pellucidum as a neuroimaging signature of head impact exposure
Rattachement africain : nl, de, gb, se. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Cavum septum pellucidum (CSP) is commonly observed upon neuroimaging examination in individuals exposed to repetitive head impacts (RHI) and post-mortem in cases with chronic traumatic encephalopathy. Consequently, CSP has been proposed as a potential biomarker for RHI-related neurodegeneration, yet prevalence estimates of CSP across other neurodegenerative diseases and its clinical implications are largely unknown. We assessed CSP prevalence and clinical correlates in individuals with RHI exposure, a history of traumatic brain injury (TBI), a neurodegenerative disease (i.e. Alzheimer’s disease or frontotemporal dementia) and normal cognition. The primary group of interest, i.e. individuals exposed to RHI in contact sports or military service (n = 65; mean exposure 21.58 years), was compared against age- and sex-matched participants with TBI (n = 57; number of TBI range: 1–5) and non-exposed participants of the Amsterdam Dementia Cohort (Alzheimer’s disease, n = 30; frontotemporal dementia, n = 24; normal cognition, n = 27). Structural 3D brain MRI scans were visually rated for CSP grade (ranging 0–4) by two raters blinded to the clinical information. A CSP of at least Grade 2 was considered enlarged/abnormal. Inter-rater reliability was assessed with Cohens’ weighted Kappa (κ). We investigated whether prevalence of enlarged CSP differed between groups and assessed associations with neuropsychological outcomes (verbal memory, processing speed, mental flexibility and semantic fluency), neuropsychiatric symptoms (neuropsychiatric inventory), ventricular enlargement as measured with Evan’s index and MRI volumes of composite regions (limbic, temporal-meta regions and the whole brain). Inter-rater reliability was substantial [κ = 0.734 (95% confidence interval 0.67–0.80)]. An enlarged CSP was more often observed in the RHI group (44.6%) compared with individuals with Alzheimer’s disease [13.3%, odds ratio (OR) = 5.24 (1.79–19.26)], frontotemporal dementia [16.7%, OR = 4.03 (1.35–15.02)] and normal cognition [18.5%, OR = 3.54 (1.27–11.62)], all PFDR < 0.05, but not compared with the TBI group [29.8%, OR = 1.90 (0.90–4.06), PFDR = 0.094]. In those with RHI, enlarged CSP was associated with lower outcomes on verbal memory learning (η² = 0.09, PFDR = 0.023) and recall (η² = 0.08, PFDR = 0.030). For TBI, enlarged CSP was associated with lower performance on verbal memory learning; however, this lost significance after multiple comparison correction (η² = 0.014, PFDR = 0.09). Enlarged CSP was not associated with the composite MRI volumes, ventricular enlargement or neuropsychiatric symptoms. In summary, enlarged CSP was more prevalent in RHI-exposed individuals compared with individuals with a neurodegenerative disease or normal cognition, but not compared with TBI, and was associated with lower verbal memory performance in the RHI group. Our study highlights enlarged CSP as a potential consequence of long-term head impact exposure and, to a lesser extent, TBI, rather than a general consequence of neurodegeneration.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Enlarged cavum septum pellucidum as a neuroimaging signature of head impact exposure
- Date Crossref
- 01/01/2025
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Amsterdam Neuroscience pays non établi dans la noticeStructure de recherche
-
Amsterdam University Medical Centers pays non établi dans la noticeÉtablissement de santé
-
Vrije Universiteit Amsterdam Neurology pays non établi dans la noticeUniversité ou école supérieure
-
Institut für Schlaganfall- und Demenzforschung pays non établi dans la noticeUniversité ou école supérieure
-
Ludwig-Maximilians-Universität München pays non établi dans la noticeUniversité ou école supérieure
-
Queen Mary University of London pays non établi dans la noticeUniversité ou école supérieure
-
National Hospital for Neurology and Neurosurgery pays non établi dans la noticeÉtablissement de santé
-
UCL Queen Square Institute of Neurology pays non établi dans la noticeUniversité ou école supérieure
-
University College London Queen Square Institute of Neurology and Centre for Medical Image Computing pays non établi dans la noticeUniversité ou école supérieure
-
Lund University Department of Clinical Sciences pays non établi dans la noticeUniversité ou école supérieure
-
Institute for Stroke and Dementia Research pays non établi dans la noticeStructure de recherche
-
Dementia Fund pays non établi dans la noticeInstitution
Amsterdam Neuroscience, Amsterdam University Medical Centers et Neurology — Vrije Universiteit Amsterdam, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.